DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

HORIZON-PFT: Pivotal Fracture Trial

Phase 3

Completed

Conditions: Osteoporosis

First Posted Date: 2002-11-15

Last Posted Date: 2011-11-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7700

Registration Number: NCT00049829

Locations: 🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 56 locations

Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2002-10-04

Last Posted Date: 2017-08-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 484

Registration Number: NCT00046748

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Phase 3

Completed

Conditions: Osteoporosis
Hip Fracture

First Posted Date: 2002-09-25

Last Posted Date: 2012-05-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2127

Registration Number: NCT00046254

Locations: 🇩🇪
Novartis, Nuernberg, Germany
🇺🇸
Radiant Research Lake Worth, Lake Worth, Florida, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

and more 25 locations

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: PKC412
Drug: Itraconazole

First Posted Date: 2002-09-18

Last Posted Date: 2017-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 144

Registration Number: NCT00045942

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2002-05-10

Last Posted Date: 2011-11-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT00036413

Locations: 🇺🇸
Neurological Institute, New York, New York, United States

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Phase 4

Completed

Conditions: Prostate Cancer

First Posted Date: 2002-05-08

Last Posted Date: 2009-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 261

Registration Number: NCT00035997

Locations: 🇺🇸
Urology Associates of Central CA, Fresno, California, United States
🇺🇸
Advanced Urology Medical Office, Los Angeles, California, United States
🇺🇸
Southwest Florida Urologic Association, Fort Myers, Florida, United States

and more 53 locations

EPO906 Therapy in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2002-05-03

Last Posted Date: 2017-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT00035113

Locations: 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸
University of Maryland - Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States

and more 2 locations

EPO906 Therapy in Patients With Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: epothilone b

First Posted Date: 2002-05-03

Last Posted Date: 2017-02-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT00035126

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colonic Neoplasms
Colorectal Neoplasms

First Posted Date: 2002-05-03

Last Posted Date: 2013-12-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT00035087

Locations: 🇺🇸
Cancer Institute of New Jersey (CINJ), New Brunswick, New Jersey, United States

EPO906 Therapy in Patients With Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: epothilone b

First Posted Date: 2002-05-03

Last Posted Date: 2012-04-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT00035165

Locations: 🇺🇸
Comprehensive Cancer Center@ Our Lady if Mercy Medical Center, Bronx, New York, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy